Impact of e-Prescribing on the Pharmaceutical Industry
Survey began 12 June 2008
Survey ended 13 August 2008
Background
“An effort to push doctors to switch from hand-writing prescriptions to using new digital technology is gaining momentum in Congress, with top Republican and Democratic lawmakers planning to include similar provisions in their versions of a key Medicare bill,” reports Richard Meyer in a post to World of DTC Marketing Blog.
For pharmaceutical manufacturers, ePrescribing may offer a new channel to influence physician prescribing at the point of care.
We would like your opinion on the impact of ePrescribing on the pharmaceutical industry, identifying the opportunities and benefits. For example, how strongly do you agree or disagree with the following statement:
- ePrescribing systems that allow access to published clinical data at the point of care can increase off-label prescribing of brand drugs.
- ePrescribing will greatly enhance pharma marketers ability to deliver brand-specific information at the point of care.
- ePrescribing will greatly diminish the prescribing of brand drugs due to better access to generic equivalents.
- ePrescribing will usher in a new era of manged care marketing due to preferred listing of drugs in formularies.
- ePrescribing can greatly improve patient compliance — especially filling the first script — and thereby increase sales of brand name drugs.
Results of this survey will be used to inform an ongoing Pharma Marketing Roundtable discussion, which you may join. This discussion and survey results will be summarized in an issue of Pharma Marketing News.
Your comments are confidential (anonymous) unless you specifically provide your contact information at the end of the survey and allow us to attribute comments to you personally.
- Sorry. No results available.
